Previous studies have shown that mutations in β-catenin, APC, and other components of the destruction complex appear very rarely in prostate cancer cells [17–19], implicating other regulatory mechanisms for activating Wnt/β-catenin signaling in promoting prostate tumorigenesis. The gene discussed is APC; the disease is prostate carcinoma.